Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: fatigue

Being Active May Reduce Risk of Chronic Low Back Pain

Shereen Lehman  |  

(Reuters Health)—Regularly engaging in physical activity, from walking to intense exercise, may help to reduce the risk of chronic low back pain by, as much as 16%, according to a new review of previous studies. In the past, it hasn’t been clear whether physical activity staves off low back pain, or people without back pain…

Rheumatology Online Educational Courses Among Key ARHP Pillars

Paul M. Adam, MSW, & Afton L. Hassett, PsyD  |  

Editor’s note: The new Pillar Talk column is developed by the ARHP Executive Committee in an effort to share information about ongoing activities related to our four pillars: Education, Practice, Research and Advocacy. The ARHP Online Education Portfolio continues to evolve and grow. The Advanced Rheumatology Course (ARC) and the Fundamentals of Rheumatology Course (FRC)…

Rheumatologist Dr. Sandra Pagnussat Recalls Journey from Patient to Physician

  |  

When she was in elementary school, Sandra Pagnussat, MD, began experiencing unrelenting pain and stiffness, first in her pinky and then in her other fingers. Her pediatrician diagnosed her with polyarticular juvenile idiopathic arthritis (JIA). In high school, Sandra decided to pursue a career in medicine and began taking advanced placement classes in biology and chemistry….

Infliximab-abda Becomes 5th Biosimilar Approved in the U.S. & Abaloparatide Approved for Osteoporosis

  |  

The FDA has approved infliximab-abda, a biosimilar for treating multiple rheumatic diseases, as well as abaloparatide for treating postmenopausal women with osteoporosis…

Rocketclips, Inc./shutterstock.com

Tips for Managing Young Adult Rheumatology Patients

Gregory Taylor, MSW, RCSW  |  

Often, young adults (18–23 years old) with rheumatic illness demonstrate poor adherence to treatment regimens, lack advocacy skills and have inadequate knowledge about diagnosis and treatment.1 Patients presenting at a transition clinic are typically comfortable with having their parents continue to be centrally involved with their care, but this is a time in life when…

BYUNG H. BAN, DO

Rheumatology Case Report: Immune-Related Aortitis Associated with Ipilimumab

Byung H. Ban, DO, Jayne L. Crowe, MD, & Robert M. Graham, MD  |  

Ipilimumab (Yervoy) is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4). It was the first drug to demonstrate a survival benefit in advanced melanoma and was approved by the FDA in 2011.1 By blocking the CTLA-4 receptor, ipilimumab enhances the immune response against tumors via cytotoxic T lymphocyte activation and proliferation.2 However, immunopotentiating…

Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA

  |  

Brodalumab Approved for Plaque Psoriasis The U.S. Food and Drug Administration has approved brodalumab, a monoclonal antibody that targets interleukin 17 (IL‑17).1,2 Brodalumab (Siliq) was approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond to, or have lost response to, other…

Fellows Forum Case Report: Neuromyelitis Optica

Atul Kapila, MD, Tayseer Haroun, MBBS, & Jayanth Doss, MD  |  

Case Presentation The patient was a 42-year-old African American female diagnosed with systemic lupus erythematosus (SLE) based on the findings of polyarthritis, malar and discoid rash, fatigue, positive double-stranded DNA (dsDNA) ribonucleoprotein and Smith antibodies, and low serum complement levels. Her SLE had been well controlled on hydroxychloroquine 400 mg daily, oral methotrexate 25 mg…

Straightforward Approach Can Help Rheumatology Health Professionals Engage with Fibromyalgia Patients

Terence Starz, MD, on behalf of the ARHP Practice Committee  |  

“I have pain all over my body” is a challenging response after you’ve asked a new patient what brings them in for their visit. You immediately suspect that this patient has fibromyalgia. The prevalence of fibromyalgia in the U.S. is 5 million people, and it is among the most common conditions in many rheumatology practices….